High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk (HDT-HIV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01045889

Recruitment Status : Completed

First Posted : January 11, 2010

Last Update Posted : August 19, 2016

Sponsor:

Information provided by (Responsible Party):

Giuseppe Rossi, Azienda Ospedaliera Spedali Civili di Brescia

Study Description

Brief Summary:

The purpose of the study is to evaluate the efficacy of an intensified first-line treatment, with conventional chemotherapy (CHOP) plus monoclonal antibody anti CD20, followed by high dose chemotherapy and PBSC transplantation in HIV-related aggressive non-Hodgkin lymphoma at "high risk" , according to the international prognostic index (IPI).

Condition or disease	Intervention/treatment	Phase
HIV-related Lymphoma HIV Infections	Other: Rituximab and CHOP regimen + PBSCT	Phase 2

Detailed Description:

HIV associated NHL show particularly aggressive clinical features and a worse prognosis compared to the general population. The recent introduction of highly active antiretroviral therapy (HAART)has improved HIV positive patients' clinical conditions and reduced the risk of opportunistic infections, thus making HIV+ patients more similar to HIV- patients. Several studies have shown that the early use (as first line treatment) of high dose chemotherapy (HDT) with peripheral blood stem cell transplantation (PBSCT) is superior in the HIV negative setting to conventional dose chemotherapy, at least in patients with poor prognostic factors at diagnosis. Recently, several experiences have shown the feasibility, safety and efficacy of HDT and PBSCT, in association with HAART, as salvage therapy in HIV positive patients with lymphoma who maintain a chemosensitive disease after first-line treatment failure. It is rationale therefore to explore the use of this treatment strategy earlier, within the upfront treatment of HIV-associated lymphoma, in those patients with poor prognostic factors at diagnosis, according to the international prognostic score (IPI).

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	27 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at "High Risk", Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation
Study Start Date :	January 2007
Actual Primary Completion Date :	May 2016
Actual Study Completion Date :	May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS Lymphoma

Drug Information available for: Rituximab

Genetic and Rare Diseases Information Center resources: Lymphosarcoma Lymphoma AIDS Related B-cell Lymphoma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: R-CHOP + PBSCT All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation	Other: Rituximab and CHOP regimen + PBSCT Other Names: Mabthera cyclophosphamide adryamicin vincristine prednisone BiCNU etoposide aracytin melphalan

Outcome Measures

Primary Outcome Measures :

Overall survival [ Time Frame: 2-years ]

Secondary Outcome Measures :

Partial and complete responses [ Time Frame: Evaluation of response one month after peripheral blood transplantation ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 60 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV positivity
"Large cell"histology (DLBCL, Immunoblastic, Plasmablastic, Anaplastic lymphoma)
Age 18-60 years
Age-adjusted IPI 2-3
Ann Arbor stage I B-IV
Written informed consent.

Exclusion Criteria:

Burkitt lymphoma
Lymphoblastic lymphoma
Primary effusion lymphoma
Age-adjusted IPI 0-1
Performance Status (WHO) >2 (if not related to lymphoma)
Inadequate cardiac function (V.E.F. < 50%) or clinically evident cardiac disease
Inadequate pulmonary function (DLCO < 50% and/or O2 < 96%)
Inadequate renal function (creatinine > 2 mg/dl)
Inadequate liver function (AST/ALT > 3 ULN and/or PT < 70%, if not related to lymphoma)
Inadequate marrow function (neutrophils < 1500/cmm; platelets < 100.000/cmm, if not related to lymphoma)
Virologic failure to HAART (including at least one NRTI, one NNRTI and two PI) and/or CD4 count < 50/cmm.
CNS or meningeal lymphoma
Active opportunistic infections
Pregnancy
Other evolutive malignancy (except of localized non-melanoma skin cancer and in situ portio carcinoma)
Any other condition that contraindicates this treatment program at discretion of physician
HBsAg positivity with active viral replication (HBV-DNA positivity)

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01045889

Locations


Italy
AO Spedali Civili di Brescia
Brescia, Italy, 25123

Sponsors and Collaborators

Azienda Ospedaliera Spedali Civili di Brescia

Investigators


Principal Investigator:	Giuseppe Rossi, MD	Haematology Division - AO Spedali Civili di Brescia - Italy

More Information

Publications:

Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spina M, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009 Aug 13;114(7):1306-13. doi: 10.1182/blood-2009-02-202762. Epub 2009 May 18.


Responsible Party:	Giuseppe Rossi, Director of Hematology, Azienda Ospedaliera Spedali Civili di Brescia
ClinicalTrials.gov Identifier:	NCT01045889 History of Changes
Other Study ID Numbers:	ema2_LNH e HIV
First Posted:	January 11, 2010 Key Record Dates
Last Update Posted:	August 19, 2016
Last Verified:	August 2016

Keywords provided by Giuseppe Rossi, Azienda Ospedaliera Spedali Civili di Brescia:


HIV non hodgkin lymphoma peripheral blood stem cell transplantation

Additional relevant MeSH terms:


Lymphoma HIV Infections Lymphoma, Non-Hodgkin Lymphoma, AIDS-Related Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral	Sexually Transmitted Diseases Immunologic Deficiency Syndromes Lymphoma, B-Cell Cyclophosphamide Rituximab Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists

To Top